ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study

Zhou, Yongjian; Zeng, Chunling; Sun, Xiaofeng; Zhang, Jun; Qu, Hongyan; Zhang, Xinhua; Zhou, Ye; Liu, Zimin; Wu, Xiaojun; Wu, Xin; Jiao, Xuelong; Shen, Lin; Zhou, Yanbing*; Wang, Yuexiang*; Li, Jian*复旦大学; 北京大学; 青岛大学; 哈尔滨医科大学; 中山大学; 中国科学院研究生院; 中国科学院; 1
ONCOLOGIST2023-2-13DOI: 10.1093/oncolo/oyac271
12阅读
引用收藏
分享

摘要

This article reports on the inhibitory effect of anlotinib in GIST cell lines with different gene mutations, evaluating the efficacy and safety of second-line treatment of GIST with anlotinib compared with second-line treatment with sunitinib in the same period. The clinical trial registration number is NCT04106024. @@@ Background Anlotinib is a multi-target tyrosine kinase inhibitor that can effectively inhibit tumor cell proliferation after receptor kinase activation caused by KIT gene mutation. Methods We tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations and evaluated the efficacy of anlotinib for patients with metastatic GIST after imatinib failure in a multicenter, single-arm, phase II study. Results In vitro, V654A mutation encoded by KIT exon 13 was intermediately sensitive to anlotinib. Moreover, anlotinib was able to partly suppress the activation loop mutation D820A from exon 17 while another activation loop mutation N822K, also from exon 17, was resistant to anlotinib. From September 2018 to October 2020, 64 patients from 9 Chinese medical centers were enrolled in this study. Seven patients had partial response and 39 patients had stable disease. The median PFS was 8.0 months. There was no statistical significance comparing with PFS of sunitinib second-line therapy at the same period. The most common adverse events related to anlotinib treatment were hypertension, neutropenia, and fatigue. Conclusion Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.

学科与关键词

关键词
gastrointestinal stromal tumoranlotinibantitumor activitysecond-line treatment
相关
加载中…
  • Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
    Li, Jian; Zhang, Jun; Zhang, Yanqiao; Qiu, Haibo; Zhou, Yanbing; Zhou, Yongjian; Zhang, Xinhua; Zhou, Ye; Zhu, Yuping; Li, Yong; Wang, Ming; Shen, Kuntang; Tao, Kaixiong; Wu, Xin; Wang, Haijiang; Zhang, Bo; Ling, Jiayu; Ye, Yingjiang; Wu, Xingye; Qu, Hongyan; Ma, Yue; Jiao, Xuelong; Zheng, Hualong; Jin, Jiejie; Liu, Zhuo; Tan, Ming; Fang, Yong; Zhang, Peng; Zhang, Nan; Lei, Cheng; Cai, Zhaolun; Liang, Bin; Peng, Zhangyan; Huang, Zhao; Dong, Juan; Shen, Lin*European Journal of Cancer, 2024, 196: 113439.
  • Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
    Li, Jian; Zhang, Xinhua; Deng, Yanhong; Wu, Xin; Zheng, Zhichao; Zhou, Yongjian; Cai, Shirong; Zhang, Yanqiao; Zhang, Jun; Tao, Kaixiong; Cui, Yuehong; Cao, Hui; Shen, Kuntang; Yu, Jiren; Zhou, Ye; Ren, Wenxiao; Qu, Chenglin; Zhao, Wanqi; Hu, Jin; Wang, Wei; Yang, Jason; Shen, Lin*ONCOLOGIST, 2023, 28(2): 187-+.被引 3
  • The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
ONCOLOGIST
发表日期
2023-02-13
DOI
10.1093/oncolo/oyac271
语言
ENGLISH
成果收录
SCIE
资助标注
Chia Tai Tianqing Pharmaceutical Group Co., Ltd

作者

  • Z

    Zhou, Yongjian (第一作者)

    fujian med univ

  • Z

    Zeng, Chunling

    cas · chinese acad sci · univ chinese acad sci

查看全部 15 位作者收起作者
  • S

    Sun, Xiaofeng

    jiangsu inst canc res · nanjing med univ

  • Z

    Zhang, Jun

    1 · chongqing med univ

  • Q

    Qu, Hongyan

    2 · harbin med univ

  • Z

    Zhang, Xinhua

    1 · sun yat sen univ

  • Z

    Zhou, Ye

    fudan univ

  • L

    Liu, Zimin

    qingdao univ

  • W

    Wu, Xiaojun

  • W

    Wu, Xin

  • J

    Jiao, Xuelong

    qingdao univ

  • S

    Shen, Lin

    beijing canc hosp & inst · peking univ

  • Z

    Zhou, Yanbing (通讯)

    qingdao univ

  • W

    Wang, Yuexiang (通讯)

    cas · chinese acad sci · univ chinese acad sci

  • L

    Li, Jian (通讯)

    beijing canc hosp & inst · peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417